However, downregulation of FOXO3 promoted DNMT3B overexpression, leading to tumor growth in lung cancer, while clinical findings also showed that there was a high DNMT3B, low FOXO3a, and high MDM2 expression associated with low survival rates in lung cancer patients (51). The gene discussed is DNMT3B; the disease is lung carcinoma.